Beta Bionics (BBNX) Stock Price

Beta Bionics Price

NYSE·CLOSED
12.83USD-1.44 (-10.63 %)
Market closed

Over the last 3 years Beta Bionics grew revenue by 724.3% annually, reaching 100.25 M USD. For Beta Bionics, the net margin of -73.0% is up versus -36,173.7% a few years ago. The consensus 12-month price target for Beta Bionics is 30.60 USD, about 138.5% above where the stock trades today. Of 17 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 45% above its 52-week low.

Beta Bionics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Beta Bionics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Beta Bionics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Beta Bionics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Beta Bionics Stock Price History
DateBeta Bionics Price
7/31/202612.83 USD
7/30/202614.27 USD
7/29/202615.13 USD
7/27/202616.09 USD
7/23/202616.13 USD
7/22/202616.31 USD
7/21/202617.62 USD
7/20/202617.82 USD
7/17/202617.29 USD
7/16/202616.90 USD
7/15/202616.86 USD
7/14/202616.86 USD
7/13/202617.10 USD
7/10/202617.03 USD
7/9/202616.43 USD
7/8/202616.50 USD
7/7/202617.00 USD
7/6/202616.82 USD
7/2/202616.76 USD
7/1/202616.70 USD
6/30/202615.67 USD
6/29/202617.00 USD
6/26/202616.82 USD
6/25/202615.91 USD
6/24/202614.73 USD
6/23/202613.67 USD
6/22/202613.54 USD
6/18/202613.59 USD
6/17/202613.96 USD
6/16/202613.67 USD
6/15/202614.48 USD
6/12/202614.57 USD
6/11/202613.88 USD
6/10/202614.34 USD
6/9/202614.39 USD
6/8/202613.87 USD
6/5/202613.90 USD
6/4/202613.46 USD
6/3/202612.74 USD
6/2/202612.75 USD
6/1/202612.68 USD
5/29/202611.97 USD
5/28/202612.02 USD
5/27/202611.86 USD
5/26/202611.66 USD
5/22/202611.76 USD
5/21/202610.18 USD
5/20/20269.92 USD
5/19/20269.42 USD
5/18/20269.40 USD
5/15/20269.46 USD
5/14/20269.20 USD
5/13/20269.63 USD
5/12/20269.82 USD
5/11/20269.85 USD
5/8/20269.65 USD
5/7/202610.50 USD
5/6/202610.57 USD
5/5/202610.01 USD
5/4/202610.22 USD
5/1/202610.29 USD
4/30/202610.20 USD
4/29/20269.90 USD
4/28/202610.08 USD
4/27/202610.65 USD
4/24/202611.17 USD
4/23/202611.43 USD
4/22/202612.20 USD
4/21/202612.27 USD
4/20/202612.91 USD
4/17/202612.98 USD
4/16/202612.18 USD
4/15/202613.02 USD
4/14/202611.81 USD
4/13/202610.63 USD
4/10/20268.86 USD
4/9/20269.63 USD
4/8/20269.79 USD
4/7/20269.73 USD
4/6/20269.95 USD
4/2/20269.93 USD
4/1/202610.01 USD
3/31/202610.02 USD
3/30/20269.86 USD
3/27/202610.76 USD
3/26/202611.52 USD
3/25/202611.31 USD
3/24/202611.24 USD
3/23/202611.02 USD
3/20/202610.70 USD
3/19/202610.80 USD
3/18/202610.63 USD
3/17/202610.64 USD
3/16/202610.87 USD
3/13/202610.39 USD
3/12/202610.11 USD
3/11/202610.87 USD
3/10/202610.97 USD
3/9/202610.87 USD
3/6/202610.61 USD
3/5/202611.11 USD
3/4/202611.38 USD
3/3/202611.57 USD
3/2/202612.52 USD
2/27/202612.63 USD
2/26/202613.02 USD
2/25/202612.89 USD
2/24/202613.39 USD
2/23/202613.76 USD
2/20/202613.70 USD
2/19/202613.46 USD
2/18/202613.61 USD
2/17/202613.97 USD
2/13/202613.94 USD
2/12/202613.55 USD
2/11/202614.12 USD
2/10/202614.78 USD
2/9/202613.87 USD
2/6/202613.08 USD
2/5/202613.24 USD
2/4/202614.09 USD
2/3/202614.46 USD
2/2/202613.70 USD
1/30/202613.83 USD
1/29/202614.79 USD
1/28/202614.78 USD
1/27/202614.93 USD
1/26/202615.46 USD
1/23/202615.96 USD
1/22/202616.50 USD
1/21/202616.47 USD
1/20/202618.43 USD
1/16/202618.50 USD
1/15/202617.79 USD
1/14/202616.99 USD
1/13/202617.27 USD
1/12/202617.65 USD
1/9/202620.14 USD
1/8/202620.14 USD
1/7/202619.83 USD
1/6/202619.77 USD
1/5/202618.62 USD
1/2/202618.41 USD
12/31/202519.18 USD
12/30/202520.13 USD
12/29/202519.69 USD
12/26/202520.06 USD
12/24/202519.57 USD
12/23/202519.74 USD
12/22/202519.95 USD
12/19/202518.41 USD
12/18/202518.30 USD
12/17/202518.38 USD
12/16/202518.65 USD
12/15/202518.71 USD
12/12/202518.74 USD
12/11/202518.45 USD
12/10/202518.38 USD
12/9/202518.26 USD
12/8/202517.82 USD
12/5/202518.50 USD
12/4/202518.89 USD
12/3/202519.14 USD
12/2/202517.91 USD
12/1/202518.59 USD
11/28/202519.73 USD
11/26/202519.43 USD
11/25/202519.84 USD
11/24/202519.77 USD
11/21/202519.78 USD
11/20/202517.88 USD
11/19/202517.45 USD
11/18/202517.07 USD
11/17/202517.10 USD
11/14/202517.11 USD
11/13/202516.52 USD
11/12/202517.73 USD
11/11/202518.14 USD
11/10/202517.31 USD
11/7/202516.56 USD
11/6/202515.76 USD
11/5/202516.69 USD
11/4/202517.51 USD
11/3/202517.44 USD
10/31/202517.14 USD
10/30/202516.86 USD
10/29/202516.87 USD
10/28/202515.29 USD
10/27/202514.95 USD
10/24/202513.19 USD
10/23/202512.60 USD
10/22/202513.36 USD
10/21/202513.21 USD
10/20/202512.74 USD
10/17/202512.60 USD
10/16/202512.99 USD
10/15/202513.30 USD
10/14/202514.06 USD
10/13/202513.95 USD
10/10/202513.24 USD
10/9/202514.00 USD
10/8/202513.93 USD
10/7/202513.95 USD
10/6/202513.82 USD
10/3/202514.01 USD
10/2/202512.90 USD
10/1/202512.72 USD
9/30/202512.51 USD
9/29/202512.50 USD
9/26/202512.30 USD
9/25/202513.93 USD
9/24/202514.31 USD
9/23/202514.40 USD
9/22/202514.42 USD
9/19/202514.14 USD
9/18/202514.51 USD
9/17/202514.55 USD
9/16/202514.66 USD
9/15/202515.93 USD
9/12/202516.63 USD
9/11/202515.95 USD
9/10/202515.66 USD
9/9/202515.74 USD
9/8/202514.56 USD
9/5/202512.72 USD
9/4/202512.65 USD
9/3/202512.39 USD
9/2/202511.97 USD
8/29/202511.86 USD
8/28/202511.78 USD
8/27/202511.94 USD
8/26/202511.54 USD
8/25/202510.99 USD
8/22/202510.73 USD
8/21/202510.63 USD
8/20/20259.63 USD
8/19/202510.00 USD
8/18/202510.87 USD
8/15/202510.73 USD
8/14/202510.52 USD
8/13/20259.51 USD
8/12/20258.95 USD
8/11/20259.00 USD
8/8/20259.28 USD
8/7/20259.50 USD
8/6/20259.57 USD
8/5/20259.95 USD
8/4/202510.34 USD
8/1/202510.32 USD
Access this data via the Eulerpool API
Get Free API Key

Beta Bionics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
12.00 M USD
-35.85 M USD
-44.10 M USD
Jan 1, 2024
65.12 M USD
-45.25 M USD
-54.76 M USD
Jan 1, 2025
100.25 M USD
-71.68 M USD
-73.20 M USD
Jan 1, 2026 (e)
133.31 M USD
-119.01 M USD
-96.21 M USD
Jan 1, 2027 (e)
179.55 M USD
-160.29 M USD
-95.08 M USD
Jan 1, 2028 (e)
251.55 M USD
-224.56 M USD
-68.16 M USD
Jan 1, 2029 (e)
343.14 M USD
-306.33 M USD
-50.62 M USD
Jan 1, 2030 (e)
466.13 M USD
-416.13 M USD
2.64 M USD

Beta Bionics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 1, 2026, 10:46 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20222023202420252026e2027e2028e2029e2030e
–11.0065.00100.00133.00179.00251.00343.00466.00
––490.9153.8533.0034.5940.2236.6535.86
–54.5553.8555.0055.0055.0055.0055.0055.00
55.006.0035.0055.0073.1598.45138.05188.65256.30
-65.00-35.00-45.00-71.00-119.00-160.00-224.00-306.00-416.00
–-318.18-69.23-71.00-89.47-89.39-89.24-89.21-89.27
-64.00-44.00-54.00-73.00-96.00-95.00-68.00-50.002.00
–-31.2522.7335.1931.51-1.04-28.42-26.47-104.00
40.536.0343.3540.5340.5340.5340.5340.5340.53
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Beta Bionics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Beta Bionics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Beta Bionics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Beta Bionics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Beta Bionics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Beta Bionics stock margins

The Beta Bionics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Beta Bionics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Beta Bionics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
100.00 %
-36,784.36 %
-36,173.74 %
Jan 1, 2023
52.59 %
-298.87 %
-367.64 %
Jan 1, 2024
55.11 %
-69.48 %
-84.08 %
Jan 1, 2025
55.40 %
-71.50 %
-73.02 %
Jan 1, 2026 (e)
55.40 %
-89.27 %
-72.17 %
Jan 1, 2027 (e)
55.40 %
-89.27 %
-52.96 %
Jan 1, 2028 (e)
55.40 %
-89.27 %
-27.10 %

Beta Bionics Stock Revenue, EBIT, Earnings per Share

The Beta Bionics earnings per share therefore indicates how much revenue Beta Bionics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
1.99 USD
-5.95 USD
-7.32 USD
Jan 1, 2024
1.50 USD
-1.04 USD
-1.26 USD
Jan 1, 2025
2.47 USD
-1.77 USD
-1.81 USD
Jan 1, 2026 (e)
3.03 USD
-2.94 USD
-2.19 USD
Jan 1, 2027 (e)
4.08 USD
-3.95 USD
-2.16 USD
Jan 1, 2028 (e)
5.71 USD
-5.54 USD
-1.55 USD

Beta Bionics business model & stock analysis

Beta Bionics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Beta Bionics Employees
Details
Date
Beta Bionics Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Beta Bionics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Beta Bionics historical P/E ratio, EBIT multiple, and P/S ratio

Beta Bionics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Beta Bionics shares outstanding

The number of shares of Beta Bionics was 40.53 M in 2025. This indicates how many shares Beta Bionics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
44.02 M Stocks
Jan 1, 2023
6.03 M Stocks
Jan 1, 2024
43.35 M Stocks
Jan 1, 2025
40.53 M Stocks
Jan 1, 2026 (e)
40.53 M Stocks
Jan 1, 2027 (e)
40.53 M Stocks
Jan 1, 2028 (e)
40.53 M Stocks

Current Beta Bionics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
7.69 %
Buy
76.47 % (13)
Hold
23.53 % (4)
Sell
0.00 % (0)
12M Price Target
30.60
Last Price
12.83
Currency
USD
12M Return Potential
138.50 %
LTM Return
0 %

Beta Bionics Analyst Rating Actions

DateFirmActionRating
7/15/2026
Goldman Sachs
Goldman Sachs
MaintainedBuy
7/13/2026
Truist Securities
Truist Securities
MaintainedBuy
5/27/2026
Goldman Sachs
Goldman Sachs
MaintainedBuy
5/18/2026
B of A Securities
B of A Securities
MaintainedNeutral
4/22/2026
Stifel
Stifel
MaintainedBuy
4/22/2026
Leerink Partners
Leerink Partners
MaintainedOutperform
4/15/2026
Truist Securities
Truist Securities
MaintainedBuy
4/9/2026
Goldman Sachs
Goldman Sachs
MaintainedBuy
2/18/2026
Stifel
Stifel
MaintainedBuy
2/18/2026
Baird
Baird
MaintainedNeutral

Beta Bionics Earnings Calls

2025

Beta Bionics Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
7/29/2026-0.61USD32.17 MUSD2026 Q2
4/21/2026-0.50USD27.50 MUSD2026 Q1
2/17/2026-0.42USD30.63 MUSD2025 Q4

Beta Bionics shareholder structure

% Name
11.20480%
Eventide Asset Management, LLC
Eventide Asset Management, LLC
9.55002%
Farallon Capital Management, L.L.C.
Farallon Capital Management, L.L.C.
8.86324%
Wellington Management Company, LLP
Wellington Management Company, LLP
8.67823%
Soleus Capital Management, L.P.
Soleus Capital Management, L.P.
8.11021%
Sands Capital Ventures LLC
Sands Capital Ventures LLC
7.49475%
RTW Investments L.P.
RTW Investments L.P.
...

Beta Bionics Beneficial Ownership Filings (SEC 13D/G)

Free Float
44.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
13.40%
Eventide Asset Management, LLC
Eventide Asset Management, LLC
SEC ↗
8.60%
Morgan Stanley
Morgan Stanley
SEC ↗
8.20%
Sands Capital Life Sciences Pulse Fund II. L.P.
Sands Capital Life Sciences Pulse Fund II. L.P.
SEC ↗
6.90%
Divisadero Street Capital Management, LP
Divisadero Street Capital Management, LP
SEC ↗
6.40%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
5.80%
Zone Healthcare Holdings, LLC
Zone Healthcare Holdings, LLC
SEC ↗
5.20%
Point72 Asset Management, L.P.
Point72 Asset Management, L.P.
SEC ↗
4.50%
RTW Investments, LP
RTW Investments, LP
SEC ↗
3.80%
Soleus Private Equity Fund II, L.P.
Soleus Private Equity Fund II, L.P.
SEC ↗
3.68%
Perceptive Advisors LLC
Perceptive Advisors LLC
SEC ↗

Beta Bionics Executives and Management Board

MH

Mr. Mark Hopman

(47)

Chief Commercial Officer

Compensation992,432.00 USD
SS

Mr. Sean Saint

(49)

President, Chief Executive Officer, Director

Compensation885,667.00 USD
SF

Mr. Stephen Feider

(35)

Chief Financial Officer

Compensation659,583.00 USD
SC

Mr. Sean Carney

(55)

Independent Director

Compensation60,000.00 USD
AL

Mr. Adam Lezack

(45)

Independent Chairman of the Board

Compensation47,500.00 USD

Frequently asked questions about Beta Bionics

Analysts currently set an average price target of 29.95 USD for the Beta Bionics stock (median: 30.60 USD), implying +133.4 % versus the latest price. The consensus is based on 17 analyst ratings.

Beta Bionics Analyst Price Targets 2026

All fundamentals and in-depth analysis of Beta Bionics

Our stock analysis for Beta Bionics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beta Bionics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Beta Bionics Stock
Beta Bionics Revenue→
Beta Bionics Stock
Beta Bionics Net Income→
Beta Bionics Stock
Beta Bionics P/E→
Beta Bionics Stock
Beta Bionics P/S→
Beta Bionics Stock
Beta Bionics EBIT→
Beta Bionics Stock
Beta Bionics Dividend→
Beta Bionics Stock
Beta Bionics Directors Dealings→
Beta Bionics Stock
Beta Bionics Stocks→
Beta Bionics Stock
Beta Bionics Market capitalization→
Beta Bionics Stock
Beta Bionics Debt→
Beta Bionics Stock
Beta Bionics Liabilities→
Beta Bionics Stock
Beta Bionics Equity→
Beta Bionics Stock
Beta Bionics AAQS→
Beta Bionics Stock
Beta Bionics Employees→
Beta Bionics Stock
Beta Bionics ROE→
Beta Bionics Stock
Beta Bionics ROA→
Beta Bionics Stock
Beta Bionics ROCE→
Beta Bionics Stock
Beta Bionics News→
Beta Bionics Stock
Beta Bionics Analyst Price Targets→

Health Stocks

Betta Pharmaceuticals CoBespoke ExtractsBetter TherapeuticsBeryl DrugsBetterLife PharmaBerry Genomics CoBeyond AirBeOne MedicinesBeyondspringBenQ Medical TechnologyBG MedicineBenitec BiopharmaAll Stocks A–Z →